7 newer rulings cite the same tariff codes.
Classification can shift over time. Review the more recent rulings below before relying on this one.
The tariff classification of an investigational vaccine from France
Issued March 14, 2005 by U.S. Customs and Border Protection.
Cite this ruling
Copies to clipboardL8 L83243 (March 14, 2005)
Tariff classification
HTS codes: 3002.20.0000
Headings: 3002
Product description
The subject product consists of an investigational vaccine intended for use in an FDA-regulated clinical trial in order to evaluate its safety and efficacy in the treatment of melanoma. The clinical trial, which will take approximately eight months to complete, is being conducted pursuant to an Investigational New Drug application filed by your firm with the FDA (IND No. 10658). The vaccine is composed of a frozen suspension of human melanoma cells in an aqueous solution of salt and sucrose. The frozen suspension will be put up in plastic freezing vials and supplied in packages containing 8 to 12 vials per package. These packages will then be shipped on dry ice directly from the manufacturer to the various clinical-trial sites in the U.S.
CBP rationale
The applicable subheading for the subject product will be 3002.20.0000, Harmonized Tariff Schedule of the United States (HTS), which provides for “Vaccines for human medicine.
Full text
NY L83243 March 14, 2005 CLA-2-30:RR:NC:2:238 L83243 CATEGORY: Classification TARIFF NO.: 3002.20.0000 Mr. Henry E. Schea III Avax Technologies, Inc. 2000 Hamilton Street, Suite 204 Philadelphia, PA 19130 RE: The tariff classification of an investigational vaccine from France Dear Mr. Schea: In your letter dated March 1, 2005, you requested a tariff classification ruling. The subject product consists of an investigational vaccine intended for use in an FDA-regulated clinical trial in order to evaluate its safety and efficacy in the treatment of melanoma. The clinical trial, which will take approximately eight months to complete, is being conducted pursuant to an Investigational New Drug application filed by your firm with the FDA (IND No. 10658). The vaccine is composed of a frozen suspension of human melanoma cells in an aqueous solution of salt and sucrose. The frozen suspension will be put up in plastic freezing vials and supplied in packages containing 8 to 12 vials per package. These packages will then be shipped on dry ice directly from the manufacturer to the various clinical-trial sites in the U.S. The applicable subheading for the subject product will be 3002.20.0000, Harmonized Tariff Schedule of the United States (HTS), which provides for “Vaccines for human medicine.” The rate of duty will be free. This merchandise may be subject to the requirements of the Federal Food, Drug, and Cosmetic Act, which is administered by the U.S. Food and Drug Administration. You may contact them at 5600 Fishers Lane, Rockville, Maryland 20857, telephone number 1-888-443-6332. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Freeze Dried BCG Vaccine and Freeze Dried Tuberculin, Purified Protein Derivative (PPD) from Japan
The tariff classification of Finished Vaccine Concentrates from France
The tariff classification of Recombinant Yellow Fever virus vaccine from France
The tariff classification of the Japanese Encephalitis virus vaccine from China
The tariff classification of Menactra Vaccine from the United Kingdom
The tariff classification, country of origin marking, and status under the United States-Australia Free Trade Agreement (UAFTA), of Influenza Virus Vaccine from Australia.
The tariff classification of Fluzone® High-Dose Influenza Virus Vaccine of United States origin put up in dosage form in France
The tariff classification of Infanrix (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) from Belgium
The tariff classification of Havrix (Hepatitis A Vaccine, Inactivated) from Belgium
The tariff classification of Engerix-B [Hepatitis B Vaccine (Recombinant)] from Belgium
Follow L83243
Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.
One email per day at most. Confirm your address once, unsubscribe anytime.
Searching CBP rulings the smart way
Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.